Press release
Kengreal Market Report by Valuates Reports
Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug[1] for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.
"Kengreal Drug Insight, 2019" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Kengreal covering the historical global sales and also provides the Kengreal sales estimation during the forecasted period (2019-2021). The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country. In addition to this, the report also provides the SWOT analysis for Kengreal and emerging therapies in this space.
View full Report: https://reports.valuates.com/sreport/DELV-DRIN-425/Kengreal_Drug_Insight_2019
Methodology
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight`s team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Scope
• A review of the Kengreal, based on information derived from company and industry-specific sources
• Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
• Coverage of the Drug Master Files and API Manufacturers by country
• Patent Expiry Timeline and Exclusivity Details
• Route of Synthesis of the API
• Forecasted Sales Figure from 2019-2021
• Market competition and emerging therapies
• SWOT Analysis
Inquire for Sample: https://reports.valuates.com/request/sample/DELV-DRIN-425/Kengreal_Drug_Insight_2019
Reasons to Buy
• Establish a comprehensive understanding of Kengreal
• Access to drug`s API manufacturers details to devise API procurement strategy for generic development
• Plan developmental timelines around drug`s patents for the major markets- US and EU
• Understand Kengreal`s current and future growth through its historical and forecasted sales
• Identify and understand the current in-market competitors for the drug
• Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
• Identify and plan ahead for prospective emerging players and their products operating in the same space as the drug
• Identify opportunities in the same area as Kengreal with DelveInsight`s SWOT analysis
Inquire for Discount: https://reports.valuates.com/request/discount/DELV-DRIN-425/Kengreal_Drug_Insight_2019
Valuates Reports
sales@valuates.com
For U.S. Toll Free Call +1 (425) 388-2538
For IST Call +91-8040957137
To know more visit us on:
Website: https://reports.valuates.com/
Linkedin: www.linkedin.com/company/valuatesreports
Facebook: www.facebook.com/valuatesreports
Twitter: www.twitter.com/valuatesreports
Instagram: www.instagram.com/reportsvaluates
Youtube: www.youtube.com/channel/UCH4wNXynaTZbiD5m92WQI4A
Our aim is to collate unparalleled Market insights and notify our customers as and when it happens. Valuates is curating premium Market Research Reports from the leading publishers around the globe. We will help you map your information needs to our report repository of Market research reports and guide you through your purchasing decision. We are based out of silicon valley of India (Bengaluru) and provide 24/7 online and offline support to all our customers and just a phone call away.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Kengreal Market Report by Valuates Reports here
News-ID: 1766754 • Views: …
More Releases from Valuates Reports
2-Oxazolidinone Market Revenue, Insights, Overview, Outlook, Analysis | Valuates …
2-Oxazolidinone Market Size
The global market for 2-Oxazolidinone was valued at US$ 732 million in the year 2024 and is projected to reach a revised size of US$ 916 million by 2031, growing at a CAGR of 3.3% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1I12558/Global_2_Oxazolidinone_Market?utm_source=Openpr&utm_medium=Referral
This report aims to provide a comprehensive presentation of the global market for 2-Oxazolidinone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess…
Strontium-88 Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Re …
Strontium-88 Market Size
The global market for Strontium-88 was valued at US$ 89 million in the year 2024 and is projected to reach a revised size of US$ 126 million by 2031, growing at a CAGR of 5.2% during the forecast period.
Download Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-34T9158/Global_Strontium_Market?utm_source=Openpr&utm_medium=Referral
This report aims to provide a comprehensive presentation of the global market for Strontium-88, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess…
Cobalt Sulfate Heptahydrate Market Revenue, Insights, Overview, Outlook, Analysi …
Cobalt Sulfate Heptahydrate Market Size
The global market for Cobalt Sulfate Heptahydrate was valued at US$ 449 million in the year 2024 and is projected to reach a revised size of US$ 729 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19T19438/Global_Cobalt_Sulfate_Heptahydrate_Market?utm_source=Openpr&utm_medium=Referral
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments…
Ultrasonic Fabric Cutting and Sealing Machine Market Revenue, Insights, Overview …
Ultrasonic Fabric Cutting and Sealing Machine Market Size
The global market for Ultrasonic Fabric Cutting and Sealing Machine was valued at US$ 1200 million in the year 2024 and is projected to reach a revised size of US$ 2091 million by 2031, growing at a CAGR of 8.2% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-12M18905/Global_Ultrasonic_Fabric_Cutting_and_Sealing_Machine_Market?utm_source=Openpr&utm_medium=Referral
This report aims to provide a comprehensive presentation of the global market for Ultrasonic Fabric Cutting and…
More Releases for Kengreal
Cangrelor Market Size, Growth Opportunities 2031 by Key Manufacturer- Cayman Che …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Cangrelor Market size was valued at USD 1200.1 Million in 2023 and is projected to reach USD 2500.2 Million by 2031, growing at a CAGR of 8.6% during the forecasted period 2024 to 2031.
What is the current outlook of the Cangrelor market?
The Cangrelor market is witnessing significant growth, driven by its role as an effective intravenous antiplatelet agent used…
Global Antiplatelet Drugs Market To Be Driven By Increasing Advancements In Phar …
The new report by Expert Market Research titled, 'Global Antiplatelet Drug Market Report and Forecast 2023-2028', gives in-depth analysis of the global antiplatelet drug market, assessing the market based on its segments like drug, drug class, applications, different routes of administration, distribution channel, and major regions.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering…
The Antiplatelet Drugs Market To Thrive Backed By Wearable Technology
Antiplatelet drugs are incorrectly referred to as blood thinners. They do not thin the blood, but interfere with the vital process by which the blood clots. Antiplatelet drugs usually reduce the aggregation of blood cells, reducing potentially harmful clots. Giving antiplatelet drugs to people at high risk of heart disease can help avoid the risk of stroke and heart attack .
Get Sample Copy of This Report @ …
North America dominates region with the number of players initiating clinical tr …
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided.
Antiplatelet agents are widely used…
